Published in final edited form as:

Tetrahedron Lett. 2012 December 19; 53(51): 6897–6900. doi:10.1016/j.tetlet.2012.09.135.

Parallel Synthesis of Structurally Diverse Aminobenzimidazole Tethered Sultams and Benzothiazepinones

Sureshbabu Dadiboyena¹ and Adel Nefzi^{1,2,*}

¹Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port St. Lucie, FL 34987 USA

²Florida Atlantic University, Boca Raton, FL 33431 USA

Abstract

A solid-phase methodology to construct aminobenzimidazole tethered sultams and benzothiazepinones from commercial amino acids, amines, carboxylic acids and sulfonyl chlorides is described. Coupling of Fmoc-Cys(Trt)-OH to resin-bound aminobenzimidazole scaffold provided an essential precursor for the construction of a variety of seven membered benzofused cyclic sulfonamides and thiazepinones via palladium catalyzed Buchwald-Hartwig type intramolecular cyclization.

Keywords

Solid-phase synthesis; Aminobenzimidazoles; sultams; cyclic sulfonamides; benzthiazepinones; intramolecular cyclization; and Heterocycles

Introduction

Solid phase organic synthesis (SPOS) is a valuable tool for the expedited parallel synthesis of structurally diverse compounds of drug discovery interest.^{1–7} Continuing with our long standing interest in the development of heterocyclic libraries utilizing resin-bound peptidyl-,^{5–7} and heterocyclic scaffolds^{7–9} as starting materials, we describe an efficient methodology for the parallel synthesis of structurally diverse aminobenzimidazole tethered sultams and benzothiazepinones. Sultams or cyclic sulfonamides are useful structural motifs in heterocyclic synthesis,⁴ applied as chiral auxiliaries in asymmetric synthesis,¹⁰ and are actively sought in the areas of antimalarial,¹¹ antiviral,¹² anticancer,¹³ antimicrobial,¹⁴ and antileukemic research.^{15,16} Likewise, aminobenzimidazole is a recurring template in the design and for the development of combinatorial libraries of drugs and drug-like molecules.^{17,18}

We previously reported the application of resin-bound aminobenzimidazoles as a template for the synthesis of a variety of fused and/or tethered heterocyclic compounds such as tetracyclic benzimidazoles,¹⁹ triazino-benzimidazoles,²⁰ branched thiohydantoin benzimidazolinethiones,²¹ and aminobenzimidazole tethered hydantoins, thiohydantoins,²²

© 2012 Elsevier Ltd. All rights reserved.

*Corresponding author: Ph: +1(772) 345 4739; Fax: +1(772) 345 3649; anefzi@tpims.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

and thiazoles.²³ In this Letter, we extend the application of this practical methodology toward the synthesis of aminobenzimidazole tethered sultams and benzothiazepinones. Our retrosynthetic rationale for the synthesis aminobenzimidazole derived cyclic sulfonamides is illustrated in Scheme 1. We envisioned the construction of benzofused cyclic sulfonamides **1** from the resin-bound free amine **2** *via* palladium catalyzed cyclization.²⁴

The parallel synthesis of the desired sulfonamides were pursued using the tea-bag approach, wherein the resin is packed within sealed polypropylene mesh packets.²⁵ The synthesis of diversified resin-bound aminobenzimidazoles **3** *via* nucleophilic substitution of 4-fluoro-3-nitrobenzoic acid were carried out according to the literature precedents.^{19–23} The resin-bound aminobenzimidazole was later coupled to Fmoc-Cys(Trt)-OH **4** in the presence of PyBOP. Following Fmoc deprotection, the generated free amine **2**^{22,23} was treated with 2-bromoarylsulfonyl chlorides to furnish the intermediate sulfonamides which, upon trityl group deprotection generated a thiol **5**. The treatment of resin-bound sulfonamides in the presence of Cs₂CO₃ and palladium led following intramolecular cyclization in a Buchwald-Hartwig fashion to the resin-bound sultams **6**.^{7,26,27} Additional third position of diversity (R₃) was introduced by the treatment of sultams with several aryl and alkyl halides **7** (Scheme 2). Following cleavage of the resin with anhydrous HF, the desired cyclic sultams **1**²⁸ were isolated in reasonable yields (Table 1).

On the basis of this result, we decided to extend the application of this protocol toward the synthesis of benzothiazepinones (Scheme 3) **8**. The reaction of the cysteine coupled to resin-bound aminobenzimidazole **2** with substituted 2-chlorobenzoic acids in the presence of DIC/HOBT, followed by cleavage of the trityl group generated the intermediate thiol which under Buchwald-Hartwig type conditions proceeded smoothly to yield the resin-bound thiazepinones **10**. Finally, the desired benzothiazepinones **8** were obtained in moderate yields after cleavage of the resin using anhydrous HF (Scheme 3).²⁹ The results are summarized in Table 2. All these above synthesized products were confirmed by LC-MS and NMR spectroscopy. The incorporated heterocyclic core in the final products, a useful pharmacophore prevalent in many bioactive compounds endowed with an array of pharmacological properties.^{30,31}

Conclusions

In conclusion, we have developed a multistep solid-phase strategy for the parallel synthesis of aminobenzimidazole tethered sultams and benzothiazepinones *via* palladium-catalyzed Buchwald-Hartwig type coupling/cyclization.^{28,29} This methodology provided a convenient pathway for the assembly of two useful seven-membered heterocyclic units and also the construction of C-S bond formation reactions.

Acknowledgments

The authors would like to thank the State of Florida Funding, NIH (1R03DA025850-01A1, Nefzi; 5P41GM081261-03, Houghten; 3P41GM079590-03S1) for providing generous financial support.

References

1. Ziegert RE, Torang J, Knepper K, Brase S. *J Comb Chem.* 2005; 7:147. [PubMed: 15762741]
2. (a) Kundu B. *Curr Opin Drug Disc Dev.* 2003; 6:815.(b) Feliu L, Vera-Luque P, Albericio F, Alvarez M. *J Comb Chem.* 2009; 11:175. [PubMed: 19053506]
3. (a) Nefzi A, Ostresh JM, Houghten RA. *Chem Rev.* 1997; 97:449. [PubMed: 11848878] (b) Park KH, Kurth MJ. *J Org Chem.* 2000; 65:3520. [PubMed: 10843640]

4. (a) Levy L. *Drugs Future*. 1992; 17:451.(b) Chen W, Li Z, Ou L, Giulianotti MA, Houghten RA, Yu Y. *Tetrahedron Lett*. 2011; 52:1456.
5. Nefzi A, Marcello G, Truong L, Rattan S, Ostresh JM, Houghten RA. *J Comb Chem*. 2002; 4:175. [PubMed: 11886293]
6. Nefzi A, Ostresh JM, Yu J, Houghten RA. *J Org Chem*. 2004; 69:3603. [PubMed: 15152987]
7. Nefzi A, Arutyunyan S, Fenwick JE. *J Org Chem*. 2010; 75:7939. [PubMed: 21113437]
8. (a) Derbel S, Ghedira K, Nefzi A. *Tetrahedron Lett*. 2010; 51:3607.(b) Hoesl CE, Nefzi A, Houghten RA. *J Comb Chem*. 2004; 6:220. [PubMed: 15002970] (c) Hoesl CE, Nefzi A, Houghten RA. *Tetrahedron Lett*. 2003; 44:3705.
9. Nefzi A, Giulianotti M, Houghten RA. *Tetrahedron Lett*. 2000; 41:2283.
10. (a) Kim BH, Curran DP. *Tetrahedron*. 2011; 49:293.(b) Zajac M, Peters R. *Org Lett*. 2007; 9:2007. [PubMed: 17447778] (c) Cui Y, He C. *Angew Chem Int Ed*. 2004; 43:4210.
11. Valente C, Guedes RC, Moreira R, Iley J, Gut J, Rosenthal PJ. *Bioorg Med Chem Lett*. 2006; 16:4115. [PubMed: 16697641]
12. Di Santo R, Costi R, Artico M, Massa S, Marongiu ME, Loi AG, De Montis A, La Colla P. *Antiviral Chem Chemother*. 1998; 9:127.
13. Scozzafava A, Owa T, Mastrolorenzo A, Supuran CT. *Curr Med Chem*. 2003; 10:925. [PubMed: 12678681]
14. Zia-ur-Rehman M, Choudary JA, Ahmad S, Siddiqui HL. *Chem Pharm Bull*. 2006; 54:1175. [PubMed: 16880664]
15. Silvestri R, Marfe G, Artico M, La Regina G, Lavecchia A, Novellino E, Morgante M, Di Stefano C, Catalano G, Filomeni G, Abruzzese E, Ciriolo MR, Russo MA, Amadori S, Cirilli R, La Torre F, Sinibaldi Salimei P. *J Med Chem*. 2006; 49:5840. [PubMed: 16970408]
16. Lebegue N, Gallet S, Flouquet N, Carato P, Pfeiffer B, Renard P, Leonce S, Pierre A, Chavatte P, Berthelot P. *J Med Chem*. 2005; 48:7363. [PubMed: 16279796]
17. (a) Franzen RG. *J Comb Chem*. 2000; 2:195. [PubMed: 10827923] (b) Krchnak V, Holladay MW. *Chem Rev*. 2002:102.
18. (a) Yu, Y.; Nefzi, A.; Ostresh, JM.; Houghten, RA. *Innovations and Perspectives in Solid Phase Synthesis and Combinatorial Libraries*. Epton, Roger, editor. Mayflower Worldwide Ltd; London UK: 2004. (b) Nefzi A, Ostresh JM, Yu Y, Houghten RA. *J Org Chem*. 2004; 69:3603. [PubMed: 15152987] (c) Nefzi A, Ostresh JM, Houghten RA. *Chem Rev*. 1997; 97:449. [PubMed: 11848878]
19. Hoesl CE, Nefzi A, Houghten RA. *J Comb Chem*. 2004; 6:220. [PubMed: 15002970]
20. Hoesl CE, Nefzi A, Houghten RA. *Tetrahedron Lett*. 2003; 44:3705.
21. Nefzi A, Giulianotti M, Houghten RA. *Tetrahedron Lett*. 2000; 41:2283.
22. Dadiboyena S, Nefzi A. *Tetrahedron Lett*. 2011; 52:7030. [PubMed: 22199408]
23. Dadiboyena S, Nefzi A. *Synthesis*. 2012; 44:215.
24. (a) Reddy CV, Kingston JV, Verkade JG. *J Org Chem*. 2008; 73:3047. [PubMed: 18370424] (b) Dehli JR, Legros J, Bolm C. *Chem Commun*. 2005:973.(c) Hill LL, Moore LR, Huang R, Craciun R, Vincent AJ, Dixon DA, Chou J, Woltermann CJ, Shaughnessy KH. *J Org Chem*. 2006; 71:5117. [PubMed: 16808497]
25. Houghten RA. *Proc Natl Acad Sci USA*. 1985; 82:5131. [PubMed: 2410914]
26. Liu L, Stelmach JE, Natarajan SR, Chen MH, Singh SB, Schwartz CD, Fitzgerald CE, O'Keefe SJ, Zaller DM, Schmatz DM, Doherty JB. *Bioorg Med Chem Lett*. 2003; 13:3979. [PubMed: 14592489]
27. Kaldor SW, Kalish VJ, Davies JF II, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH. *J Med Chem*. 1997; 40:3979. [PubMed: 9397180]
28. *General Procedure for the Solid-Phase Synthesis of Aminobenzimidazole tethered Sultams: p*-Methylbenzhydrylamine (MBHA) resin (100 mg, 1.10 meq/g, 100–200 mesh) was sealed inside a polypropylene mesh packet. Polypropylene bottles were used for all of the reactions. Fmoc-Amino acid (Fmoc-Cys(Trt)-OH) coupled resin bound aminobenzimidazoles were synthesized according

to a previous literature.^{22,23} Following Fmoc deprotection with a solution of 20% piperidine in DMF and washings, the dried resin-bound free amine **2** was treated with corresponding benzenesulfonyl chlorides (10 eq., 0.2M in anhydrous DCM) and DIEA (10 eq.). The resulting resin was stirred at room temperature (8h), and the resin was washed with DMF (2x), MeOH (2x), and DCM (2x). Deprotection of the Trityl group with 6% TFA/DCM (1% TIPS) for 15 min (3x), the resin **5** was washed with DCM (2x). The palladium-catalyzed cyclization was performed under anhydrous conditions. The resin-bound sulfonamides were treated with Cs₂CO₃ (10 eq., 0.2 M in anhyd. DMF), Pd(PPh₃)₄ (0.2 eq.) and (±)-BINAP (0.4 eq.), and the whole reaction mixture was heated at 100 °C for 14 h. The resin was then washed with DMF (2x), DCM (2x) and methanol (2x). Diverse alkyl halides were tethered to the resin-bound sultams in the presence of DIEA in the DMF at room temperature for 36 h and the resulting resin was washed with DMF (3x), and DCM (3x). The resin was cleaved with HF/anisole for 90 min at 0°C, and the final sultams **1** were obtained following extraction with 95% AcOH in H₂O and lyophilization as a white powder. The aminobenzimidazole tethered sultams **1** were purified by preparative reverse-phase HPLC and the products were characterized by LC-MS (ESI) conditions. *NMR data for entry 1b*: ¹H NMR (DMSO-*d*₆): 0.91 (t, *J* = 8Hz, 3H), 1.25–1.35 (m, 2H), 1.69–1.77 (m, 2H), 3.02–3.06 (m, 1H), 3.56–3.61 (m, 1H), 4.21 (t, *J* = 8Hz, 1H), 4.48 (dt, *J* = 8Hz, 12Hz, 1H), 7.51–7.58 (m, 4H), 7.60–7.65 (m, 3H), 7.67–7.70 (m, 1H), 7.80 (d, *J* = 8Hz, 1H), 7.94–7.97 (m, 2H), 8.01 (m, 1H); LC-MS *m/z* data calcd. for C₂₁H₂₃N₅O₄S₂(MH⁺): 473.57; found: 474.3; *NMR data for entry 1g*: ¹H NMR (DMSO-*d*₆): 0.84 (t, *J* = 8Hz, 2H), 0.93 (t, *J* = 8Hz, 2H), 1.17–1.24 (m, 1H), 1.31–1.36 (m, 1H), 1.58–1.63 (m, 2H), 3.92–4.01 (m, 1H), 4.08–4.12 (m, 1H), 6.51 (s, 2H), 7.28 (d, *J* = 8Hz, 1H), 7.46 (d, *J* = 8Hz, 1H), 7.58 (d, *J* = 8Hz, 1H), 7.68 (d, *J* = 8Hz, 1H), 7.81 (d, *J* = 8Hz, 1H), 7.87 (d, *J* = 8Hz, 1H), 7.99 (d, *J* = 16Hz, 2H), 8.13–8.14 (m, 2H); LC-MS *m/z* data calcd. for C₂₂H₂₂F₃N₅O₄S₂(MH⁺): 541.57; found: 542.4; *NMR data for entry 1i*: ¹H NMR (DMSO-*d*₆): 0.87 (d, *J* = 8Hz, 3H), 0.83 (d, *J* = 8Hz, 4H), 0.92–0.96 (m, 1H), 2.03 (s, 4H), 2.51 (m, 5H), 3.88 (dd, *J* = 8Hz, 12Hz, 1H), 3.96 (dd, *J* = 8Hz, 16Hz, 1H), 6.51 (s, 1H), 7.33 (br s, 1H), 7.59 (d, *J* = 8Hz, 1H), 7.70 (d, *J* = 8Hz, 1H), 7.81 (d, *J* = 8Hz, 1H), 7.00 (d, *J* = 8Hz, 1H), 7.97–8.01 (m, 2H), 8.15 (br s, 2H); LC-MS *m/z* data calcd. for C₃₀H₃₀FN₅O₂S₂(MH⁺): 661.71; found: 662.5; *NMR data for entry 1m*: ¹H NMR (DMSO-*d*₆): 0.88 (d, *J* = 8Hz, 3H), 1.25–1.30 (m, 2H), 1.67–1.72 (m, 2H), 2.97–3.03 (m, 1H), 3.50 (d, *J* = 8Hz, 1H), 4.19 (t, *J* = 8Hz, 1H), 4.42 (t, *J* = 8Hz, 1H), 5.42 (d, *J* = 4Hz, 1H), 7.26–7.35 (m, 8H), 7.46–7.54 (m, 3H), 7.63–7.71 (m, 3H), 7.86–7.96 (m, 1H), 7.99–8.03 (m, 2H); LC-MS *m/z* data calcd. for C₂₈H₂₉N₅O₄S₂(MH⁺): 563.70; found: 564.6.

29. *General Procedure for the Synthesis of Aminobenzimidazole tethered benzothiazepinones*: The resin-bound free amine **2** was coupled with substituted 2-chlorobenzoic acids using DIC (8 eq., 0.2M in DMF) and HOBt (8 eq.) conditions for 8 hrs, and the resulting resin bound amides were washed with DMF (2x) and DCM (2x). The trityl group was cleaved with 6% TFA/DCM (1% TIPS) for 15 min (3x), and the resin **9** was washed with DCM (2x) and dried overnight. The palladium-catalyzed cyclization was performed under anhydrous conditions. The resin-bound intermediate amides **9** were treated with Cs₂CO₃ (10 eq., 0.2M in anhyd. DMF), Pd(PPh₃)₄ (0.2 eq.) and (±)-BINAP (0.4 eq.), and the whole reaction mixture was heated at 100 °C for 10h. The resin was then washed with DMF (2x), DCM (2x) and methanol (2x). The resin was cleaved with HF/anisole for 90 min at 0°C, and the desired benzothiazepinones **8** were obtained following extraction with 95% AcOH in H₂O and lyophilization as a white powder. The aminobenzimidazole tethered benzothiazepinones **8** were purified by preparative reverse-phase HPLC and the products were characterized by LC-MS under ESI conditions. *NMR data for entry 8b*: ¹H NMR (DMSO-*d*₆): 0.81 (t, *J* = 8Hz, 3H), 1.21–1.28 (m, 2H), 1.64–1.72 (m, 2H), 4.17 (t, *J* = 8Hz, 2H), 6.05 (br s, 1H), 6.41 (br s, 1H), 6.59 (br s, 1H), 7.31 (m, 1H), 7.49–7.62 (m, 6H), 7.72 (d, *J* = 8Hz, 1H), 7.81 (d, *J* = 8Hz, 1H), 8.00–8.02 (m, 2H); LC-MS *m/z* data calcd. for C₂₂H₂₃N₅O₃S(MH⁺): 437.51; found: 440.0; *NMR data for entry 8i*: ¹H NMR (DMSO-*d*₆): 0.90–1.05 (m, 6H), 1.45 (d, *J* = 12Hz, 2H), 1.55–1.56 (m, 4H), 1.79–1.84 (m, 1H), 2.03 (s, 1H), 3.98 (d, *J* = 8Hz, 2H), 6.00 (s, 1H), 6.36 (s, 1H), 7.30 (br s, 1H), 7.54–7.60 (m, 2H), 7.73–7.81 (m, 3H), 7.95 (br s, 1H), 8.02 (s, 1H); LC-MS *m/z* data calcd. for C₂₅H₂₆ClN₅O₃S(MH⁺): 512.02; found: 514.0;
30. (a) Levai A, Kiss-Szikszai A. ARKIVOC. 2008; i:65.(b) Sainsbury, M. Comprehensive Heterocyclic Chemistry. Boulton, AJ.; McKillop, A., editors. Vol. 3. Pergamon Press; Oxford: 1984. p. 1036(c) Ferrari R. Eur Heart J. 1997; 18(Suppl A):A56. [PubMed: 9049540] (d) Salimbeni, A.; Caliarì, S.; Fici, F.; Manghisi, E. US Patent. 5,571,807. 1996. Chem Abstr. 1992;

- 116:255647x.(e) Narita H, Gaino M, Suzuki T, Kurosawa H, Inoue H, Nagao T. Chem Pharm Bull. 1990; 38:407. [PubMed: 2337956] (f) Hamanaka, ES.; Hayward, CM.; Hawkins, JM. US Patent. 5,770,594. 1998. Chem Abstr. 1996; 125:168038s.(g) Lerch, U.; Henning, R. US Patent. 4,831,028. 1989. Chem Abstr. 1988; 108:37851c.
31. (a) Henning, R.; Lerch, U.; Kaiser, J. US Patent. 4,595,685. 1986. Chem Abstr. 1986; 104:88571m. (b) Rampe D, Triggle DJ. Prog Drug Res. 1993; 40:191. [PubMed: 8395066] (c) Chaffman M, Brogden RN. Drugs. 1985; 29:387. [PubMed: 3891302] (d) Katritzsky AR, Odens HH, Zhang S. J Org Chem. 2001; 66:6792. [PubMed: 11578236] (e) Levai A. J Heterocycl Chem. 2000; 37:199.

Scheme 1.

Retrosynthetic illustration of aminobenzimidazole tethered sultams

Scheme 2.

(a) PyBOP (8 eq., 0.5M anhyd. DMF), HOBT (8 eq.), DIEA (8 eq.), 12h, r.t.; (b) 20% piperidine/DMF, 15 min (2x), r.t.; (c) DIEA (10 eq.), R_2SO_2Cl (10 eq.) 12h, r.t.; (d) 6% TFA/DCM (1% TIPS), 15 min (2x); (e) CS_2CO_3 (10 eq.), $Pd(PPh_3)_4$ (0.2 eq.), ($\pm$)-BINAP (0.4 eq.), anhydrous DMF, 100 °C, 16h; (f) R_3I , DIEA (8 eq., in 0.2M DMF); (g) HF, anisole (99:5), 0 °C, 90 min

Scheme 3.

Reagents and conditions: (a) DIC (8 eq., 0.5M anhyd. DMF), HOBt (8 eq.), 8h, r.t.; (b) 6% TFA/DCM (1% TIPS), 15 min (2x); (c) Cs₂CO₃ (10 eq.), Pd(PPh₃)₄ (0.2 eq.), (±)-BINAP (0.4 eq.), anhydrous DMF, 100 °C, 16h; (d) HF, anisole (99:5), 0 °C, 90 min

Table 1

Entry	R ₁	R ₂	R ₃	Mass calcd./found	Yield(%) ^a
1a	Cyclopentyl	H	H	485.6/486.4 (MH ⁺)	44
1b	<i>n</i> -Butyl	H	H	473.5/474.3 (MH ⁺)	47
1c	<i>i</i> -Butyl	H	H	473.5/474.4 (MH ⁺)	53
1d	Cyclohexanemethyl	H	H	513.6/514.5 (MH ⁺)	42
1e	3-(trifluoromethyl)benzyl	H	H	575.6/576.5 (MH ⁺)	56
1f	Cyclopentyl	CF ₃	H	553.6/554.5 (MH ⁺)	22
1g	<i>n</i> -Butyl	CF ₃	H	541.5/542.4 (MH ⁺)	24
1h	<i>i</i> -Butyl	CF ₃	H	541.5/542.4 (MH ⁺)	18
1i	Cyclohexanemethyl	CF ₃	H	581.6/582.4 (MH ⁺)	25
1j	3-(trifluoromethyl)benzyl	CF ₃	H	643.6/644.4 (MH ⁺)	15
1k	<i>i</i> -Butyl	H	4-OMe-Bn	593.7/594.5 (MH ⁺)	16
1l	<i>i</i> -Butyl	CF ₃	4-OMe-Bn	661.7/662.5 (MH ⁺)	18
1m	<i>n</i> -Butyl	H	Bn	563.7/564.6 (MH ⁺)	32
1n	<i>n</i> -Butyl	CF ₃	Bn	631.7/632.5 (MH ⁺)	36
1o	3-(trifluoromethyl)benzyl	H	Et	603.6/604.5 (MH ⁺)	23
1p	3-(trifluoromethyl)benzyl	CF ₃	Et	671.6/672.5 (MH ⁺)	12

Isolated yields of aminobenzimidazole tethered sultams: The products were run on a Vydac column, gradients 5 to 95% formic acid in ACN in 7 min.

^aThe yields are based on the weight of purified products and are relatives to the initial loading of the resin.

Table 2

Entry	R ₁	R ₂	Mass calcd./found	Yield(%) ^a
8a	Cyclopentyl	H	449.6/452.0 (MH ⁺)	32
8b	<i>n</i> -Butyl	H	437.5/440.0 (MH ⁺)	43
8c	<i>i</i> -Butyl	H	437.6/440.1 (MH ⁺)	60
8d	Cyclohexanemethyl	H	477.6/480.0 (MH ⁺)	51
8e	3-(trifluoromethyl)benzyl	H	539.6/542.0 (MH ⁺)	53
8f	Cyclopentyl	Cl	484.2/486.0 (MH ⁺)	16
8g	<i>n</i> -Butyl	Cl	472.1/474.0 (MH ⁺)	38
8h	<i>i</i> -Butyl	Cl	472.2/474.0 (MH ⁺)	11
8i	Cyclohexanemethyl	Cl	512.1/514.0 (MH ⁺)	18
8j	3-(trifluoromethyl)benzyl	Cl	574.2/576.0 (MH ⁺)	34

Isolated yields of aminobenzimidazole tethered thiazepinones. The products were run on a Vydac column, gradients 5 to 95% formic acid in ACN in 7 min.

^aThe yields are based on the weight of purified products and are relatives to the initial loading of the resin.